Floatz logo

Ladiratuzumab Vedotin

Hormone Receptor-Positive Breast Cancer

Seagen Inc.antibody_drug_conjugatePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

117 Active assets in the Hormone Receptor-Positive Breast Cancer cohort.

Asset / SponsorPhaseRating
Everolimus
Ellipses Pharma
Phase 4BBB
EXEMESTANE
Fujian Cancer Hospital
Phase 4BBB
Arimidex
University of Illinois at Chicago
Phase 4BBB
Ribociclib
BeOne Medicines
Phase 4BBB
Palbociclib
BeOne Medicines
Phase 3BBB

View all 50 →

Same molecule, other indications

Ladiratuzumab Vedotin is also rated in:

triple-negative breast carcinomaDormant
BB
Indicative ·
65 / 100
View asset →
HER2 positive breast carcinomaDormant
B
Indicative ·
59 / 100
View asset →
angiosarcomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →